Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336980 | 0.87 | EGFR (0.41) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10044900 | 0.87 | CA12 (0.48) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1685962 | 0.86 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL16079758 | 0.85 | ALDH1A1 (0.60) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL889415 | 0.85 | EGFR (0.51) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| Laquinimod SCHEMBL4695786 | 0.84 | TP53 (0.44) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10044898 | 0.84 | HDAC4 (0.58) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10044899 | 0.84 | ALDH1A1 (0.53) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2574422 | 0.83 | EGFR (0.47) | EGFRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10044897 | 0.83 | KDM4E (0.51) | MEN1KMT2AALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140592-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2018-05-24 | — | — | US | claimed |
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2017-11-16 | — | — | US | claimed |
| US-20160279121-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMA (IL) | 2016-09-29 | — | — | US | claimed |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-06-09 | — | — | US | claimed |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-02-18 | — | — | US | claimed |
| EP-2970129-A2 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2016-01-20 | — | — | EP | claimed |
| US-9233927-B2 | Crystals of laquinimod sodium and improved process for the manufacture thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-12 | — | — | US | claimed |
| WO-2014153145-A2 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2014-09-25 | — | — | WO | claimed |
| US-20140271878-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-09-18 | — | — | US | claimed |
| EP-2590653-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-05-15 | — | — | EP | claimed |
| US-20120010239-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | ACTIVE BIOTECH AB (SE) | 2012-01-12 | — | — | US | claimed |
| WO-2012006544-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-01-12 | — | — | WO | claimed |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | US | claimed |
| US-20230202982-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-QUINOLINE-3-CARBOXAMIDE POTASSIUM SALT FOR TREATING INFLAMMATORY BOWEL DISEASES | AQILION AB (SE) | 2023-06-29 | — | — | US | disclosed |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | AQILION AB (SE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | AQILION AB (SE) | 2023-06-01 | — | — | US | disclosed |
| EP-1511732-B1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-6875869-B2 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-04-05 | — | — | US | disclosed |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140592-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | HLA-DRB1, HAAO, RECQL | EGFR 4590/4885MEN1 3798/4885KMT2A 82/4885 |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TLR7, MYD88, PDE7A | EGFR 3387/4885MEN1 3210/4885KMT2A 237/4885 |
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, MTX2 | EGFR 4716/4885MEN1 3789/4885KMT2A 15/4885 |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | CYP4F3, HTR3C, CYP3A43 | EGFR 2694/4885MEN1 2749/4885KMT2A 2359/4885 |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ADH5, RPS4Y1, CYP4F3 | EGFR 1829/4885MEN1 2560/4885KMT2A 2223/4885 |
| US-20140271878-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, TLR7 | EGFR 4768/4885MEN1 3589/4885KMT2A 14/4885 |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, TLR7 | EGFR 4709/4885MEN1 3899/4885KMT2A 15/4885 |
| US-20160279121-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | SLC10A2, SI, ALPI | EGFR 3568/4885MEN1 2883/4885KMT2A 3547/4885 |
| US-20120010239-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
| US-20230202982-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-QUINOLINE-3-CARBOXAMIDE POTASSIUM SALT FOR TREATING INFLAMMATORY BOWEL DISEASES | SLC10A2, KCNK5, KCNQ5 | EGFR 4451/4885MEN1 2958/4885KMT2A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.